Immune functional assay for immunosuppressive management in post-transplant malignancy (original) (raw)
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients
Alex Gutiérrez-Dalmau
Drugs, 2007
View PDFchevron_right
Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients
Damiana faè
Frontiers in Oncology
View PDFchevron_right
Epidemiology of de novo malignancies after solid-organ transplantation: Immunosuppression, infection and other risk factors
Pierluca Piselli
Best Practice & Research Clinical Obstetrics & Gynaecology, 2014
View PDFchevron_right
The janus face of immunosuppression – de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich
Markus Rentsch
Kidney International, 2007
View PDFchevron_right
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management
John Fung
Clinical Transplantation, 2003
View PDFchevron_right
Toward the Definition of Immunosuppressive Regimens With Antitumor Activity
Fabio Casadio
Transplantation Proceedings, 2005
View PDFchevron_right
De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin
Peter Neuhaus
Cancer, 1997
View PDFchevron_right
Effect of immunosuppressive treatment protocol on malignancy development in renal transplant patients
Gokhan Moray
Transplantation Proceedings, 2002
View PDFchevron_right
Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy
MESUT İZZET TITIZ
Transplantation Proceedings, 2015
View PDFchevron_right
Influence of immunosuppression on the prevalence of cancer after kidney transplantation
julio pascual
Transplantation Proceedings, 2003
View PDFchevron_right
Acute Rejection, T-Cell–Depleting Antibodies, and Cancer After Transplantation
Maggie Ma
Transplantation, 2014
View PDFchevron_right
Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients
Dr. Maria Shipkova
Therapeutic Drug Monitoring, 2010
View PDFchevron_right
Is the Intracellular ATP Concentration of CD4+ T-Cells a Predictive Biomarker of Immune Status in Stable Transplant Recipients?
Carlos Benitez
Transplantation, 2009
View PDFchevron_right
Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT
Moshe Israeli
Bone Marrow Transplantation, 2010
View PDFchevron_right
Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy
Laurentia Gales
Journal of Oncology, 2021
View PDFchevron_right
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Arjang Ruhparwar, Christian Gleissner
Drug Design, Development and Therapy, 2014
View PDFchevron_right
Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
Atish Mohanty
Biomedicines
View PDFchevron_right
Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy
Sahar Zadeh
Blood, 2008
View PDFchevron_right
Effects of the New Immunosuppressive Agents on the Occurrence of Malignancies After Renal Transplantation
Maite Rivera Gorrin
Transplantation Proceedings, 2010
View PDFchevron_right
Malignancy after renal transplantation: Incidence and role of type of immunosuppression
Michael Edwardes
Annals of Surgical Oncology, 2002
View PDFchevron_right
Long-term immunosuppression and malignancy in thoracic transplantation: Where is the balance?
Nandini Nair
The Journal of Heart and Lung Transplantation, 2014
View PDFchevron_right
New concepts and best practices for management of pre- and post-transplantation cancer
Martin Prieto
Transplantation reviews (Orlando, Fla.)
View PDFchevron_right
Use of immune function test in monitoring immunosuppression in liver transplant recipients
Helen Te
Clinical Transplantation, 2012
View PDFchevron_right
Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients
Emma Taylor
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015
View PDFchevron_right
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study
Michele Santangelo
BioMed Research International, 2015
View PDFchevron_right
Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis
Javier Tejedor-Tejada
Transplantation Proceedings, 2020
View PDFchevron_right